Search

Displaying results 6561 - 6570 of 10000 in total
  1. Drug

    Efmarodocokin alfa

    go.drugbank.com/drugs/DB16398
    Investigational

    Efmarodocokin alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

    Synonyms: HUMAN INTERLEUKIN 22 (1-146), FUSED TO HUMAN IMMUNOGLOBULIN HEAVY CONSTANT GAMMA 4 (CH1(97-98), H(S10>P(158)), CH2(N67>G(227)))-(147-377), DIMER (156-156':159-159')-BISDISULFIDE, PRODUCED IN CHO CELLS,, INTERLEUKIN 22 (HUMAN (MATURE)) FUSION PROTEIN WITH IMMUNOGLOBULIN G4 (SYNTHETIC HUMAN .GAMMA.4-CHAIN FC REGION (81-GLYCINE)), DIMER
  2. Drug

    Regdanvimab

    go.drugbank.com/drugs/DB16405
    ApprovedWithdrawn

    Regdanvimab (CT-P59) is a recombinant human IgG1 monoclonal antibody directed at the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. … Trials investigating the use of regdanvimab as a therapeutic candidate for the treatment of COVID-19 began in mid-2020.

  3. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    Tiragolumab

    go.drugbank.com/drugs/DB16409
    Investigational

    Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small

  5. Drug

    Volagidemab

    go.drugbank.com/drugs/DB16421
    Investigational

    Volagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).

  6. Drug

    Rintatolimod

    go.drugbank.com/drugs/DB16425
    Investigational

    Synonyms: POLY(5')-INOSINYL-(3'->) DUPLEX WITH POLY(DODECAKIS(3')-CYTIDYLYL-(5'->)3')-URIDYLYL-(5'->), 5'-INOSINIC ACID, HOMOPOLYMER, COMPLEX WITH 5'-CYTIDYLIC ACID POLYMER WITH 5'-URIDYLIC ACID (1:1)Categories: Poly C, Poly I
  7. Drug

    VXA-CoV2-1

    go.drugbank.com/drugs/DB16433
    Investigational

    VXA-CoV2-1 is a non-replicating adenoviral vector-based oral tableted vaccine candidate that expresses a SARS-CoV-2 antigen and dsRNA adjuvant[L30493]. … This oral vaccine aims to induce immunogenicity through induction of potent serum neutralizing antibodies to the SARS-CoV-2 spike protein, induction of mucosal immune responses, and induction of T-cell

  8. Drug

    AdimrSC-2f

    go.drugbank.com/drugs/DB16436
    Investigational

    A phase I study (NCT04522089) will investigate the safety and immunogenicity of the vaccine[L30553, L30548]. … The AdimrSC-2f (SARS-CoV-2) vaccine is developed through Adimmune Corporation, the only influenza vaccine manufacturer with both EU GMP and US FDA certification in Asia[L30553].

  9. Drug

    Ganulameran

    go.drugbank.com/drugs/DB16442
    Investigational

    As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). … Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology.

  10. Drug

    Efprezimod alfa

    go.drugbank.com/drugs/DB16448
    Investigational

    CD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.